Charles Bruce G, Miller Ann K, Nasveld Peter E, Reid Mark G, Harris Ivor E, Edstein Michael D
The University of Queensland, Brisbane, QLD, Australia.
Antimicrob Agents Chemother. 2007 Aug;51(8):2709-15. doi: 10.1128/AAC.01183-06. Epub 2007 May 21.
The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine concentrations were determined by liquid chromatography-tandem mass spectrometry. Population modeling was performed with NONMEM, using a one-compartment model. Typical values of the first-order absorption rate constant (K(a)), clearance (CL/F), and volume of distribution (V/F) were 0.243 h(-1), 0.056 liters/h/kg, and 23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and 22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half-life was 12.7 days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200 samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentration-time profiles simulated (n = 1,000) from the final model. Individual pharmacokinetic estimates for tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection. No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter values for subjects with and without drug-associated moderate or severe adverse events. This validated population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used for long-term malaria prophylaxis in a large cohort of soldiers on military deployment.
对服用他非诺喹预防疟疾的澳大利亚士兵进行了他非诺喹的群体药代动力学研究。受试者(476名男性和14名女性)每天接受200mg他非诺喹碱基的负荷剂量,持续3天,随后每周服用200mg他非诺喹,持续6个月。在最后一次负荷剂量后以及第4、8和16周从每个受试者采集血样。采用液相色谱-串联质谱法测定血浆他非诺喹浓度。使用NONMEM进行群体建模,采用单室模型。一级吸收速率常数(K(a))、清除率(CL/F)和分布容积(V/F)的典型值分别为0.243 h(-1)、0.056升/小时/千克和23.7升/千克。CL/F和V/F的受试者间变异性(变异系数)分别为18%和22%。CL/F的给药间隔间变异性为18%,平均消除半衰期为12.7天。发现体重与CL/F和V/F之间存在正线性关联,但这种影响不足以保证进行剂量调整。通过非参数自举法(200个样本)评估模型稳健性。退化的视觉预测检查表明,原始数据反映了从最终模型模拟的给药后浓度-时间曲线(n = 1000)。对于4名复发间日疟原虫疟疾的受试者,他非诺喹的个体药代动力学估计未预测该药物的预防效果,因为他们的药代动力学与未感染疟疾的受试者相似。在有或没有药物相关中度或重度不良事件的受试者中,血浆他非诺喹浓度与药代动力学参数值之间不存在明显模式。这个经过验证的群体药代动力学模型令人满意地描述了在一大群军事部署士兵中长期预防疟疾使用他非诺喹的处置和变异性。